Equities research analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research report issued on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Up 2.9 %
NASDAQ EVOK opened at $5.32 on Friday. The firm has a market capitalization of $45.74 million, a price-to-earnings ratio of -2.91 and a beta of 0.39. The firm’s 50 day simple moving average is $4.80 and its 200 day simple moving average is $5.67. Evoke Pharma has a 1 year low of $3.54 and a 1 year high of $17.88.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). The firm had revenue of $2.55 million for the quarter. Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- 3 Fintech Stocks With Good 2021 Prospects
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What Are Dividend Achievers? An Introduction
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Insider Buying Explained: What Investors Need to Know
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
